Shares of Endocyte Inc. (NASDAQ:ECYT) dropped 4.9% on Wednesday . The stock traded as low as $2.98 and last traded at $3.11, with a volume of 262,845 shares traded. The stock had previously closed at $3.27.

ECYT has been the subject of several research analyst reports. Zacks Investment Research upgraded Endocyte from a “sell” rating to a “hold” rating in a research report on Tuesday, July 5th. Credit Suisse Group AG restated a “buy” rating on shares of Endocyte in a research note on Tuesday, July 12th. Cowen and Company restated a “buy” rating on shares of Endocyte in a research note on Wednesday, May 4th. Finally, Wedbush restated an “outperform” rating and set a $8.00 price target on shares of Endocyte in a research note on Wednesday, May 4th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company. Endocyte has an average rating of “Buy” and an average price target of $11.15.

The company’s market cap is $131.02 million. The stock’s 50-day moving average is $3.15 and its 200-day moving average is $3.41.

Endocyte (NASDAQ:ECYT) last issued its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($0.25) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.26) by $0.01. During the same period last year, the firm posted ($0.25) EPS. Equities research analysts expect that Endocyte Inc. will post ($1.12) EPS for the current fiscal year.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.